Ceribell, Inc. CBLL 深 沪
已收盘 04-02 16:00:00 美东时间
18.57
+0.070
+0.38%
华盛通- 最 高18.79
- 今 开18.20
- 成交量 21.78万股
- 最 低 18.06
- 昨 收 18.50
- 总市值 6.99亿
- 52周最高 24.33
- 市盈率 静 --
- 换手率 0.58%
- 52周最低 10.85
- 委 比 46.12%
- 总股本 3764.12万
- 历史最高 32.7489
- 量 比 0.67
- 振 幅 3.95%
- 历史最低 10.01
- 每 手 1
- 风险率 3.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多电话会总结 ｜ CeriBell(CBLL)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据CeriBell业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - Q4 2025营收2,480万美元，同比增长34% - 全年2025营收8,910万美元，同比增长36% - 产品收入：Q4为1,880万美元（同比增长33%），全年6,730万美元（同比增长34%） - 订阅收入：Q4为600万美元（同比增长37%），全年2,170万美元（同比增长41%） **盈利能力：** - 毛利率：Q4为87%，全年为88% - Q4毛利率较去年同期的88%略有下降，主要受中国进口产品关税上调的部分季度影响 - 全年毛利率
02-25 12:18
CeriBell Sees FY2026 Sales $111.000M-$115.000M vs $112.629M Est
CeriBell (NASDAQ:CBLL) sees FY2026 sales of $111.000 million-$115.000 million vs $112.629 million analyst estimate.
02-25 05:24
CeriBell Q4 EPS $(0.36) Beats $(0.41) Estimate, Sales $24.784M Beat $23.942M Estimate
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.41) by 12.62 percent. This is a 10 percent increase over losses of $(0.40) per share from the same
02-25 05:24
Earnings Scheduled For February 24, 2026
Companies Reporting Before The Bell • China Yuchai Intl (NYSE:CYD) is expected ...
02-24 19:11
CeriBell's Earnings: A Preview
CeriBell (NASDAQ:CBLL) will release its quarterly earnings report on Tuesday, 2...
02-24 03:01
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
BTIG Reiterates Buy on CeriBell, Maintains $30 Price Target
BTIG analyst Marie Thibault reiterates CeriBell (NASDAQ:CBLL) with a Buy and maintains $30 price target.
01-28 21:32
Analysts’ Top Healthcare Picks: Ceribell, Inc. (CBLL), Evommune, Inc. (EVMN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
01-06 01:50
Protara, CeriBell rise on FDA breakthrough designations
Protara Therapeutics (TARA) and CeriBell (CBLL) were among the notable healthcare gainers on Monday after the FDA issued breakthrough designations for their experimental products, TARA-002 cell-based ...
01-06 00:00
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Ceribell, Inc. has received FDA Breakthrough Device Designation for its AI-based LVO stroke detection monitor, which uses EEG signals to enable early detection of large vessel occlusion strokes in hospitalized patients. This technology aims to address delays in stroke detection and treatment, improving outcomes for vulnerable patients.
01-05 13:00
